Onkolojik Aciller

Ferlay J, Soerjomataram I, Ervik M et al., GLOBOCAN 2012 v1.0, Estimated Cancer Incidence Mortality and Prevalance Worldwide: IARC CancerBase,No.11,

WHO (2018), The Global Cancer Observatory 2019, (24.06.20 tarihinde https://gco.iarc.fr/today/data/factsheets/populations/792-turkey-fact-sheets.pdf adresinden ulaşılmıştır)

Rosenberg PS, Alter BP, Bolyard AA, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood. 2006;107(12):4628–35

Lewis MA, Hendrickson AW, Moynihan TJ. Oncologic emergencies: pathophysiology, presentation, diagnosis, and treatment [published correction appears in CA Cancer J Clin. 2011;61(6):420]. CA Cancer J Clin. 2011;61(5):287–314.

Patel A, Gruber P. Severe infections in neutropenic patients. Curr Opin Crit Care. 2015;21(6):586–592.

Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56–93.

Melendez E, Harper MB. Risk of serious bacterial infection in isolated and unsuspected neutropenia. Acad Emerg Med. 2010;17(2):163–7.

Rolston KV. New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin Infect Dis. 1999;29(3):515–521. doi: 10.1086/598624.

Rosa RG, Goldani LZ. Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia. Antimicrob Agents Chemother. 2014;58(7):3799–3803.

Averbuch D, Orasch C, Cordonnier C, ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013;98:1826–35.

Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. J Clin Oncol. 2017;35:2082–94.

Aguilar-Guisado M, Espigado I, Martín-Peña A, et al. Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial. Lancet Haematol. 2017;4:e573–83.

Mikulska M, Viscoli C, Orasch C, Livermore DM, et al. Etiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect. 2014; 68(4):321-31. doi: 10.1016/j.jinf.2013.12.006.

Trecarichi EM, Pagano L, Martino B,et al. Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem re-sistance in a multicentre prospective survey. Am J Hematol 2016; 91(11):1076-1081. doi: 10.1002/ajh.24489

Francesc Escrihuela-Vidal, Júlia Laporte, Adaia Albasanz-Puig and Carlota Gudiol . Update on the management of febrile neutropenia in hematologic patients. Rev Esp Quimioter.2019; 32(Suppl 2): 55–58.

Aguilar-Guisado M, Espigado I, Martín-Peña A, et al. Optimisation of empirical antimicrobial ther-apy in patients with haematological malignancies and febrile neu-tropenia (How Long study): an open-label, randomised, controlled phase 4 trial. Lancet Haematol 2017; 4:e573-e583. doi: 10.1016/S2352-3026(17)30211-9

Mc Curdy M. T. and Wacker D. A. (2018). Selected Oncologic Emergencies Rosen's Emergency Medicine: Concepts and Clinical Practice Chapter 115 (S. 1497-1508),

Khan UA, Shanholtz CB, McCurdy MT. Oncologic mechanical emergencies. Emerg Med Clin North Am. 2014;32(3):495–508.

Mc Curdy MT, Shanholtz CB. Oncologic emergencies. Crit Care Med. 2012;40(7):2212–2222.

De Jager CP, et al: “Benign” superior vena cava syndrome. Intensive Care Med 39:572–573, 2013.

Shaikh I, et al: Thrombogenic catheter-associated superior vena cava syndrome. Case Rep Emerg Med 2013:793054, 2013.

Shaheen K: Alraies MC: Superior vena cava syndrome. Cleve Clin J Med 79:410–412, 2012.

Sobrinho G, Aguiar P: Stent placement for the treatment of malignant superior vena cava syndrome—a single-center series of 56 patients. Arch Bronconeumol 50:135–140, 2014.

Belay Y, Yirdaw K, Enawgaw B. Tumor lysis syndrome in patients with hematological malignancies. J Oncol. 2017;2017 9684909.

Mirrakhimov AE. Tumor lysis syndrome: a clinical review. World J Crit Care Med. 2015;4(2):130

Wilson FP, Berns JS. Tumor lysis syndrome: new challenges and recent advances. Adv Chronic Kidney Dis. 2014;21(1):18–26.

Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–1854.

Mark L. Higdon, Do; Charles J. Arkinson, MD; and Kelley V. Lawrence et al. Oncologic Emergencies: Recognition and Initial Management, Am Fam Physician. 2018 Jun 1;97(11):741-748.

Jeremy D. Sperling (2013), Introduction to Oncologic Emergencies, Section XX Hematology and Oncology Management (1665-1678e.1)

Klemencic S., Perkins J., Diagnosis and Management of Oncologic Emergencies. West J Emerg Med. 2019; 20(2): 316–322. doi: 10.5811/westjem.2018.12.37335

Wagner J, Arora S. Oncologic metabolic emergencies. Emerg Med Clin North Am. 2014;32(3):509–525.

Takai M, Yamauchi T, Ookura M, et al. Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies—a single institution's, pharmacokinetic and pilot prospective study. Anticancer Res. 2014;34(12):7287–7296.

Cairo MS, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149(4):578–86.

Will A, Tholouli E. The clinical management of tumour lysis syndrome in haematological malignancies. Br J Haematol. 2011;154(1):3–13.

Holdsworth MT, Nguyen P. Role of i.v. allopurinol and rasburicase in tumor lysis syndrome. Am J Health Syst Pharm. 2003;60(21):2213–22.

Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. J Clin Oncol. 2010;28(27):4207–13.

Osner MH, Dalkin AC. Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia. Clin J Am Soc Nephrol. 2012;7(10):1722–172

Rosner MH, Dalkin AC. Onco-Nephrology: The pathophysiology and treatment of malignancy-associated hypercalcemia. Clin J Am Soc Nephrol. 2012;7(10):1722–1729

Sargent JT, Smith OP: Haematological emergencies managing hypercalcaemia in adults and children with haematological disorders. Br J Haematol 149:465–477, 2010.

Pettifer A, Grant S. The management of hypercalcaemia in advanced cancer. Int J Palliat Nurs. 2013;19(7):327–331.

Clines GA. Mechanisms and treatment of hypercalcemia of malignancy. Curr Opin Endocrinol Diabetes Obes. 2011;18(6):339–346.

Mundy GR, Guise TA. Hypercalcemia of malignancy. Am J Med. 1997;103(2):134–45.

Zhang SJ, et al: Analysis on survival and prognostic factors for cancer patients with malignancy-associated hypercalcemia. Asian Pac J Cancer Prev 14:6715–6719, 2013.

Behl D, et al: Oncologic emergencies. Crit Care Clin 26:181–205, 2010.

Legrand SB. Modern management of malignant hypercalcemia. Am J Hosp Palliat Care. 2011;28(7):515–7.

Sternlicht H, Glezerman IG. Hypercalcemia of malignancy and new treatment options. Ther Clin Risk Manag. 2015;11:1779–88.

Yeung, Sai-Ching J, Wenli L. Metabolic and endocrine oncologic emergencies. In: Manzullo EF, editor. Oncologic Emergencies. Houston, Texas: MD Anderson Cancer Series; 2016. pp. 21–54.

Reagan P, Pani A, Rosner MH. Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy. Am J Kidney Dis. 2014;63(1):141–7.